Active Biotech's partner Teva presents data on laquinimod for the treatment of multiple sclerosis at 31st ECTRIMS Congress
(Thomson Reuters ONE) -
Lund, October 6, 2015 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces
that the collaboration partner Teva Pharmaceutical Industries Ltd. (NYSE and
TASE: TEVA) will present data on laquinimod, an investigational therapy being
evaluated in relapsing and progressive forms of MS, at the 31(st) European
Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress in
Barcelona, October 7-10, 2015.
For further information, please see www.tevapharm.com.
About Laquinimod
Laquinimod is a once-daily oral, investigational, CNS-active immunomodulator
with a novel mechanism of action being developed for the treatment of relapsing-
remitting MS (RRMS), progressive MS and Huntington's disease. The global, Phase
III, clinical development program evaluating laquinimod in MS includes two
completed pivotal studies, ALLEGRO and BRAVO (both 0.6mg/day). A third Phase III
trial, CONCERTO, is currently ongoing and evaluating two doses of laquinimod
(0.6mg and 1.2mg/day) in 2,199 patients for up to 24 months. The primary outcome
measure is time to three-month confirmed-disability progression as measured by
the Expanded Disability Status Scale (EDSS).
For further information, please contact:
Tomas Leanderson, President & CEO
Tel +46 46 19 20 95
Email: tomas.leanderson(at)activebiotech.com
Hans Kolam, CFO
Tel +46 46 19 20 44
Email: hans.kolam(at)activebiotech.com
Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company
with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory properties, is
in pivotal phase III development for the treatment of relapsing remitting
multiple sclerosis. Also, laquinimod is in phase II development for the
treatment of primary progressive multiple sclerosis and Huntington's disease.
Furthermore, commercial activities are ongoing for the projects ISI, ANYARA and
paquinimod. Please visit www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act and/or the
Financial Instruments Trading Act. This information was provided to the media
for publication at 2:00 p.m. CEST on Oct 6, 2015.
Active Biotech?s partner Teva presents data on laquinimod:
http://hugin.info/1002/R/1956964/712899.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via GlobeNewswire
[HUG#1956964]
Unternehmensinformation / Kurzprofil:
Datum: 06.10.2015 - 14:01 Uhr
Sprache: Deutsch
News-ID 425072
Anzahl Zeichen: 3394
contact information:
Town:
LUND
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 171 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Active Biotech's partner Teva presents data on laquinimod for the treatment of multiple sclerosis at 31st ECTRIMS Congress"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
